

Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd Ramghat road ,Aligarh 202001
Collected at	: J.R.K MEDICARE CENTER		

Test Report

Test Name	Results	Units	Bio. Ref. Interval
-----------	---------	-------	--------------------

SwasthFit Super 4

LIVER & KIDNEY PANEL, SERUM

(Spectrophotometry, Indirect ISE)

Creatinine	2.57	mg/dL	0.51 - 0.95
GFR Estimated	23	mL/min/1.73m2	>59
GFR Category	G4		
Urea	42.87	mg/dL	17.00 - 43.00
Urea Nitrogen Blood	20.02	mg/dL	6.00 - 20.00
BUN/Creatinine Ratio	8		
Uric Acid	3.99	mg/dL	2.60 - 6.00
AST (SGOT)	20.8	U/L	<35
ALT (SGPT)	14.7	U/L	<35
GGTP	11.4	U/L	<38
Alkaline Phosphatase (ALP)	61.30	U/L	30 - 120
Bilirubin Total	0.56	mg/dL	0.30 - 1.20
Bilirubin Direct	0.11	mg/dL	<0.20
Bilirubin Indirect	0.45	mg/dL	<1.10
Total Protein	6.48	g/dL	6.40 - 8.30
Albumin	3.88	g/dL	3.50 - 5.20
A : G Ratio	1.49		0.90 - 2.00
Globulin(Calculated)	2.60	gm/dL	2.0 - 3.5
Calcium, Total	8.56	mg/dL	8.80 - 10.60



Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd Ramghat road ,Aligarh 202001
Collected at	: J.R.K MEDICARE CENTER		

Test Report

Test Name	Results	Units	Bio. Ref. Interval
Phosphorus	2.64	mg/dL	2.40 - 4.40
Sodium	140.00	mEq/L	136.00 - 146.00
Potassium	3.82	mEq/L	3.50 - 5.10
Chloride	105.30	mEq/L	101.00 - 109.00

Advise

1. CKD Risk Map (Z1014)
2. Cystatin C, serum (B173)

Note

1. Estimated GFR (eGFR) calculated using the 2021 CKD-EPI creatinine equation and GFR Category reported as per KDIGO guideline 2012.
2. eGFR category G1 or G2 does not fulfil the criteria for CKD, in the absence of evidence of kidney damage
3. The BUN-to-creatinine ratio is used to differentiate prerenal and postrenal azotemia from renal azotemia. Because of considerable variability, it should be used only as a rough guide. Normally, the BUN/creatinine ratio is about 10:1

LIPID SCREEN, SERUM

(CHO-POD)

Cholesterol, Total	177.00	mg/dL	<200.00
Triglycerides	88.20	mg/dL	<150.00
HDL Cholesterol	62.50	mg/dL	>50.00
LDL Cholesterol, Calculated	96.86	mg/dL	<100.00
VLDL Cholesterol, Calculated	17.64	mg/dL	<30.00
Non-HDL Cholesterol	115	mg/dL	<130

Note

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.



Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd Ramghat road ,Aligarh 202001
Collected at	: J.R.K MEDICARE CENTER		

Test Report

Test Name	Results	Units	Bio. Ref. Interval
2. Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL			
3. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk factors			
4. Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense LDL particles, a pattern known as atherogenic dyslipidemia			
5. Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL remnants, Chylomicron remnants & Lp(a)			
6. LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary treatment target			
7. Apolipoprotein B is an, secondary lipid target for treatment once LDL & Non HDL goals have been achieved			
8. Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement			

Treatment Goals as per Lipid Association of India 2020

RISK CATEGORY	TREATMENT GOAL		CONSIDER THERAPY	
	LDL CHOLESTEROL (LDL-C) (mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)	LDL CHOLESTEROL (LDL-C) (mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)
Extreme Risk Group Category A	<50 (Optional goal ≤30)	<80 (Optional goal ≤60)	≥50	≥80
Extreme Risk Group Category A	≤30	≤60	>30	>60
Very High	<50	<80	≥50	≥80
High	<70	<100	≥70	≥100
Moderate	<100	<130	≥100	≥130
Low	<100	<130	≥130*	≥160*

*In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months



Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd Ramghat road ,Aligarh 202001
Collected at	: J.R.K MEDICARE CENTER		

Test Report

Test Name	Results	Units	Bio. Ref. Interval
-----------	---------	-------	--------------------



Name : Mrs. ARCHANA SINGH
 Lab No. : 391356887
 Ref By : Dr. R K GUPTA
 Collected : 9/8/2023 10:22:00AM
 A/c Status : P
 Collected at : J.R.K MEDICARE CENTER
 Age : 43 Years
 Gender : Female
 Reported : 10/8/2023 10:44:47AM
 Report Status : Final
 Processed at : Dr. Lal Path Labs Ltd
 Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
COMPLETE BLOOD COUNT;CBC (SLS Method, Sheath Flow DC Detection Method, Fluorescent Flow Cytometry & Calculated)			
Hemoglobin	10.70	g/dL	12.00 - 15.00
Packed Cell Volume (PCV)	34.30	%	36.00 - 46.00
RBC Count	3.28	mill/mm3	3.80 - 4.80
MCV	104.60	fL	83.00 - 101.00
MCH	32.60	pg	27.00 - 32.00
MCHC	31.20	g/dL	31.50 - 34.50
Red Cell Distribution Width (RDW)	14.60	%	11.60 - 14.00
Total Leukocyte Count (TLC)	4.24	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	68.40	%	40.00 - 80.00
Lymphocytes	25.50	%	20.00 - 40.00
Monocytes	3.50	%	2.00 - 10.00
Eosinophils	2.40	%	1.00 - 6.00
Basophils	0.20	%	<2.00
Absolute Leucocyte Count			
Neutrophils	2.90	thou/mm3	2.00 - 7.00
Lymphocytes	1.08	thou/mm3	1.00 - 3.00
Monocytes	0.15	thou/mm3	0.20 - 1.00
Eosinophils	0.10	thou/mm3	0.02 - 0.50
Basophils	0.01	thou/mm3	0.02 - 0.10
Platelet Count	149	thou/mm3	150.00 - 410.00
Mean Platelet Volume	11.7	fL	6.5 - 12.0

Note

- As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of



Name : Mrs. ARCHANA SINGH
Lab No. : 391356887
Ref By : Dr. R K GUPTA
Collected : 9/8/2023 10:22:00AM
A/c Status : P
Collected at : J.R.K MEDICARE CENTER
Age : 43 Years
Gender : Female
Reported : 10/8/2023 10:44:47AM
Report Status : Final
Processed at : Dr. Lal Path Labs Ltd
Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
-----------	---------	-------	--------------------

blood

2. Test conducted on EDTA whole blood



Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd
Collected at	: J.R.K MEDICARE CENTER		: Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HPLC)			
HbA1c	5.2	%	4.00 - 5.60
Estimated average glucose (eAG)	103	mg/dL	

Interpretation

HbA1c result is suggestive of non diabetic adults (>=18 years)/ well controlled Diabetes in a known Diabetic

Interpretation as per American Diabetes Association (ADA) Guidelines

Reference Group	Non diabetic adults >=18 years	At risk (Prediabetes)	Diagnosing Diabetes	Therapeutic goals for glycemc control
HbA1c in %	4.0-5.6	5.7-6.4	>= 6.5	<7.0

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the HbA1C result does not correlate with the patient's blood glucose levels.

FACTORS THAT INTERFERE WITH HbA1C MEASUREMENT	FACTORS THAT AFFECT INTERPRETATION OF HbA1C RESULTS
Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements	Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c



Name : Mrs. ARCHANA SINGH	Age : 43 Years
Lab No. : 391356887	Gender : Female
Ref By : Dr. R K GUPTA	Reported : 10/8/2023 10:44:47AM
Collected : 9/8/2023 10:22:00AM	Report Status : Final
A/c Status : P	Processed at : Dr. Lal Path Labs Ltd
Collected at : J.R.K MEDICARE CENTER	Processed at : Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
GLUCOSE, FASTING (F), PLASMA (Hexokinase)	87.90	mg/dL	70.00 - 100.00
VITAMIN B12; CYANOCOBALAMIN, SERUM (CLIA)	57.00	pg/mL	180.00 - 914.00

Interpretation

Remarks	Result In pg/mL
Normal	180 - 914
Indeterminate	120 - 180
Deficient	< 120

Notes

1. Interpretation of the result should be considered in relation to clinical circumstances.
2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is more specific
3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking antibodies, MMA measurement should be considered in such patients
4. The concentration of Vitamin B12 obtained with different assay methods cannot be used interchangeably due to differences in assay methods and reagent specificity

VITAMIN D, 25 - HYDROXY, SERUM (CLIA)	26.70	nmol/L	75.00 - 250
---	--------------	--------	-------------

Interpretation

LEVEL	REFERENCE RANGE IN nmol/L	COMMENTS
Deficient	< 50	High risk for developing bone disease
Insufficient	50-74	Vitamin D concentration which normalizes Parathyroid hormone concentration



Name : Mrs. ARCHANA SINGH	Age : 43 Years
Lab No. : 391356887	Gender : Female
Ref By : Dr. R K GUPTA	Reported : 10/8/2023 10:44:47AM
Collected : 9/8/2023 10:22:00AM	Report Status : Final
A/c Status : P	Processed at : Dr. Lal Path Labs Ltd
Collected at : J.R.K MEDICARE CENTER	Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
Sufficient	75-250	optimal concentration for maximal health benefit	
Potential intoxication	>250	High risk for toxic effects	

Note

- The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
- 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
- Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
- It shows seasonal variation, with values being 40-50% lower in winter than in summer.
- Levels vary with age and are increased in pregnancy.
- A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments

Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels

- Inadequate exposure to sunlight
- Dietary deficiency
- Vitamin D malabsorption
- Severe Hepatocellular disease
- Drugs like Anticonvulsants
- Nephrotic syndrome

Increased levels

Vitamin D intoxication



Name	: Mrs. ARCHANA SINGH	Age	: 43 Years
Lab No.	: 391356887	Gender	: Female
Ref By	: Dr. R K GUPTA	Reported	: 10/8/2023 10:44:47AM
Collected	: 9/8/2023 10:22:00AM	Report Status	: Final
A/c Status	: P	Processed at	: Dr. Lal Path Labs Ltd Ramghat road ,Aligarh 202001
Collected at	: J.R.K MEDICARE CENTER		

Test Report

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE,TOTAL, SERUM (CLIA)			
T3, Total	0.85	ng/mL	0.70 - 2.04
T4, Total	11.58	µg/dL	5.74 - 13.03
TSH	5.99	µIU/mL	0.34 - 5.60

Note

1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has influence on the measured serum TSH concentrations.
2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or Total T4 levels especially in pregnancy and in patients on steroid therapy.
3. Unbound fraction (Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate more closely with clinical status of the patient than total T4/T3 concentration
4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals



Interpretation

PREGNANCY	REFERENCE RANGE FOR TSH IN µIU/mL (As per American Thyroid Association)
1st Trimester	0.100 - 2.500
2nd Trimester	0.200 - 3.000
3rd Trimester	0.300- 3.000



Name : Mrs. ARCHANA SINGH
Lab No. : 391356887 Age : 43 Years
Ref By : Dr. R K GUPTA Gender : Female
Collected : 9/8/2023 10:22:00AM Reported : 10/8/2023 10:44:47AM
A/c Status : P Report Status : Final
Collected at : J.R.K MEDICARE CENTER Processed at : Dr. Lal Path Labs Ltd
Ramghat road ,Aligarh 202001

Test Report

Test Name	Results	Units	Bio. Ref. Interval
 Dr. Anu Agarwal MD Pathology Chief of Laboratory Dr Lal PathLabs Ltd	 Dr. Megha Kakkar MBBS,MD (Pathology) Chief of Laboratory Dr Lal PathLabs Ltd		

-----End of report-----



IMPORTANT INSTRUCTIONS

•Test results released pertain to the specimen submitted. •All test results are dependent on the quality of the sample received by the Laboratory .
•Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician . •Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted. •Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting. •Test results may show interlaboratory variations. •The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s). •Test results are not valid for medico legal purposes. •This is computer generated medical diagnostic report that has been validated by Authorized Medical Practitioner/Doctor. •The report does not need physical signature.

(#) Sample drawn from outside source.

If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.

Tel: +91-11-49885050, Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com

